Cigna GLP-1 Coverage for Weight Loss (2026)
If you searched “does Cigna cover GLP-1s” recently, you probably ran into a headline from June 2026 saying Cigna dropped coverage of GLP-1 obesity medications. Take a breath. That story is real, but it is widely misread, and it may not apply to you. Here is what actually happened, what Cigna’s own coverage policies say as of 2026-10-16, and how to find out where your own plan stands.
Transformation Health is an independent guide, not a provider, and is not affiliated with Cigna: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
First, the headline that confused everyone
In June 2026, Reuters reported that Cigna was dropping coverage of GLP-1 medications for weight loss. What most of the shares and summaries left out is the scope: that change applied to Cigna’s own employee health plan, the Cigna Group Medical Plan, effective July 1, 2026.[1]
According to the report, a Cigna spokesperson said plans outside that employee plan were not affected, and coverage of GLP-1 medications for type 2 diabetes was not affected either.[1] If your insurance card says Cigna, that headline by itself did not remove your benefit. Your coverage is still determined the same way it was before: by what your plan includes.
It is fair to read the move as a signal of how one large company weighed the cost of these medications for its own employees. It is not accurate to read it as “Cigna no longer covers GLP-1s.” Those are different things, and the difference matters if you are trying to figure out your own next step.
The short answer for your plan
Coverage depends on your specific employer plan. As of 2026-10-16, Cigna’s own drug coverage policies state that weight loss medications are specifically excluded under many benefit plans, for both employer groups and individual and family plans, and that your plan document always takes priority over the coverage policy.[2] So the real question is not “does Cigna cover GLP-1s,” it is “does my plan include weight loss medications.” Some plans do. Many do not.
GLP-1 medications prescribed for type 2 diabetes are a separate coverage category, with their own criteria. This page is about coverage for weight management.
How Cigna handles weight loss GLP-1s
Where the benefit exists, prior authorization applies. Cigna publishes its criteria in drug coverage policies. As of 2026-10-16, the policies for Wegovy injection and for Zepbound list these adult criteria for weight management:[3][4]
| Question | What Cigna’s published policies say (as of 2026-10-16) |
|---|---|
| Are weight loss drugs covered on every plan? | No. Cigna states they are specifically excluded under many benefit plans; your plan document controls[2] |
| If covered, is prior authorization required? | Yes[3][4] |
| Age | 18 or older |
| BMI criteria | Baseline BMI of 30 or higher, or 27 or higher with at least one listed weight-related condition (such as high blood pressure, type 2 diabetes, dyslipidemia, or obstructive sleep apnea) |
| Lifestyle documentation | A trial of behavioral modification and dietary restriction for at least 3 months, and continued use alongside a reduced-calorie diet |
| First approval | 8 months |
| Renewal requirement | A loss of at least 5 percent of baseline body weight; renewals are approved for 1 year |
| Member cost cap option | A monthly copay limit, only on plans whose sponsor adopted the Evernorth benefit option announced May 21, 2025[5] |
Not every Cigna policy uses the same thresholds. A separate Cigna policy, effective April 30, 2026, uses a baseline BMI of 35 or higher, or 27 or higher with at least two listed weight-related conditions.[2] Which version applies depends on your plan, and your plan documents are the only version that counts for you.
Cigna’s pharmacy benefits business, Evernorth, also offers employers GLP-1 cost programs. On May 21, 2025, Evernorth announced a pharmacy benefit option for employers and other plan sponsors that limits the member’s monthly copay for Wegovy and Zepbound for weight loss to a set maximum, with the copay counting toward the deductible. In the same announcement, Evernorth described its separate EncircleRx program as a financial model with more than 9 million enrolled lives.[5] Neither applies unless your plan sponsor chooses it, so ask whether your plan participates.
What changed in 2025 and 2026
May 21, 2025. Evernorth announced a benefit option that limits the member’s monthly copay for Wegovy and Zepbound for weight loss, for plan sponsors that adopt it.[5]
April 30, 2026. A Cigna drug coverage policy with stricter BMI thresholds (35 or higher, or 27 or higher with two weight-related conditions) took effect for the plans it applies to.[2]
June 2026. Reuters reported that Cigna would end weight loss GLP-1 coverage on its own employee plan. The story spread widely without the scope attached.[1]
July 1, 2026. That employee plan change took effect. Plans outside the employee plan were not affected, according to the report.[1]
September 1, 2026. Cigna’s current Zepbound coverage policy took effect.[4]
The pattern to take away: Cigna publishes and revises these policies regularly, and employers revisit their own plan decisions every plan year. A benefit you have this year is worth confirming again at open enrollment.
How to check your own plan in ten minutes
You do not need to interpret headlines, and you do not need to wait for a denial letter. Three routes, fastest first:
Ask your benefits administrator at work. The single decisive fact is whether your plan includes weight loss medication coverage. HR or your benefits portal can answer that directly. While you are at it, ask whether the plan participates in an Evernorth GLP-1 cost cap or similar program.
Call member services. Use the number on your card and ask three questions. Does my plan include coverage for weight loss medications? If so, which GLP-1 medications are on the formulary and which prior authorization policy applies? And does my plan participate in a program that caps my monthly out-of-pocket cost?
Check your plan’s formulary and drug policy. Log in to your member portal and search the drug list for semaglutide or tirzepatide. Pay attention to the indication notes; a listing under diabetes coverage does not mean weight management is covered.
If the benefit exists, your next step is the paperwork. Our guide to GLP-1 prior authorization walks through the documentation these requests usually need, including the BMI record and lifestyle-effort notes that Cigna’s criteria ask for.
If your plan says no
Plenty of people with Cigna cards land here, through no fault of their own. What you do next depends on why the answer was no.
The denial was about criteria or documentation. This is often fixable. A documented BMI from a recent visit, weight-related conditions noted explicitly in your chart, and at least three months of recorded lifestyle efforts address the criteria above. HealthCare.gov says you generally have 180 days from a denial notice to file an internal appeal, and if that appeal is denied, you can in many cases ask for an independent external review.[6][7] Start with our guide on what to do when insurance denies your GLP-1.
Your plan does not include the benefit. An appeal generally cannot override a plan exclusion, because the medication is not a covered benefit on your plan. You can ask HR whether weight loss coverage or an Evernorth cost cap is under consideration for the next plan year, check whether another plan at open enrollment includes it, and ask your prescriber whether any covered indication applies to you. Beyond that, the options are outside insurance:
- Manufacturer savings and self-pay options. Novo Nordisk and Eli Lilly each publish savings and self-pay terms, and the terms change. Our page on GLP-1 savings programs compares them.
- Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[8] Our page on compounded GLP-1 without insurance explains how that route works.
Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. The full insurance coverage overview can help you weigh the options side by side.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] Niasse A. “Cigna drops coverage of GLP-1 obesity drugs for its own employees.” Reuters, June 2026, as carried by InsuranceNewsNet. Accessed 2026-10-16. https://insurancenewsnet.com/oarticle/cigna-drops-coverage-of-glp-1-obesity-drugs-for-its-own-employees
[2] Cigna. Drug Coverage Policy IP0739, “Weight Loss - Glucagon-Like Peptide-1 Agonists BMI >= 35” (includes the statement that weight loss medications are specifically excluded under many benefit plans). Effective 04/30/2026. Accessed 2026-10-16. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0739_coveragepositioncriteria_weight_loss_glp1_bmi_35.pdf
[3] Cigna National Formulary Coverage. “Weight Loss - Glucagon-Like Peptide-1 Agonists - Wegovy Injection Prior Authorization Policy.” Review date 06/17/2026. Accessed 2026-10-16. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_1010_coveragepositioncriteria_weight_loss_glp1_agonists_wegovy_injection_pa.pdf
[4] Cigna. Drug Coverage Policy IP0816, “Weight Loss - Glucagon-Like Peptide-1 Agonists - Zepbound.” Effective 09/01/2026. Accessed 2026-10-16. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0816_coveragepositioncriteria_weight_loss_zepbound.pdf
[5] Evernorth. “Evernorth launches new benefit option that drives lower net cost for weight loss medicines” (news release), May 21, 2025. Accessed 2026-10-16. https://www.evernorth.com/articles/evernorth-launches-new-benefit-option-drives-lower-net-cost-weight-loss-medicines
[6] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
[7] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
[8] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important disclosures
Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. It does not represent the terms of your specific plan and is not legal advice. Confirm current benefits, formulary status, and prior authorization requirements directly with Cigna member services or your plan administrator.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Cigna, Evernorth, and EncircleRx are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by Cigna, Evernorth, Novo Nordisk, or Eli Lilly. Transformation Health does not accept payment from providers. How we make money.